<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Vikshit</title>
	<atom:link href="http://www.tapanray.in/tag/vikshit/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pills and Payments: India&#8217;s Unethical Drug Marketing Problem</title>
		<link>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pills-and-payments-indias-unethical-drug-marketing-problem</link>
		<comments>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/#comments</comments>
		<pubDate>Fri, 27 Jun 2025 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10925</guid>
		<description><![CDATA[The recent exposé by The Economic Times, titled &#8220;Rx Name Unethical practitioners,&#8221; published on June 19, 2025, which brought to light allegations of a prominent global pharmaceutical company sponsoring extravagant foreign trips for doctors in violation of ethical codes, serves as &#8230; <a href="http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Curbing Patent Evergreening: Advancing Innovation and Health Equity for a Vikshit Bharat</title>
		<link>http://www.tapanray.in/curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat</link>
		<comments>http://www.tapanray.in/curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat/#comments</comments>
		<pubDate>Sat, 03 May 2025 07:43:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents Act]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Secondary patents]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10892</guid>
		<description><![CDATA[As published in The Economic Times of April 27, 2025:  India’s Commerce and industry minister - “Piyush Goyal stated that India frequently receives requests to extend pharmaceutical patents for minor modifications. He criticized this practice, known as &#8216;evergreening,&#8217; for prioritizing corporate profits over &#8230; <a href="http://www.tapanray.in/curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/curbing-patent-evergreening-advancing-innovation-and-health-equity-for-a-vikshit-bharat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MAGA vs. Viksit Bharat: Trump&#8217;s Tariffs And India&#8217;s Pharma Dreams</title>
		<link>http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams</link>
		<comments>http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/#comments</comments>
		<pubDate>Tue, 15 Apr 2025 08:32:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[dreams]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MAGA]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reciprocal]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tariff]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10888</guid>
		<description><![CDATA[A high-stakes clash poses a potential threat to PM Modi&#8217;s &#8216;Viksit Bharat&#8217; Vision, exposing India&#8217;s pharmaceutical vulnerability and forcing a strategic reckoning. The resurgence of Donald Trump&#8217;s &#8220;America First&#8221; MAGA (Make America Great Again) agenda casts a long, ominous shadow &#8230; <a href="http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
